Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE.

Banach, Maciej; López-Sendon, José Luis; Averna, Maurizio; Cariou, Bertrand; Loy, Megan; Manvelian, Garen; Batsu, Isabela; Poulouin, Yann; Gaudet, Daniel

Banach, Maciej; López-Sendon, José Luis; Averna, Maurizio; Cariou, Bertrand; Loy, Megan; Manvelian, Garen; Batsu, Isabela; Poulouin, Yann; Gaudet, Daniel.

Afiliación

Banach M; Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Lodz, Poland.
López-Sendon JL; Hospital Universitario La Paz, IdiPaz, CIBER-CV, UAM, Madrid, Spain.
Averna M; Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties - PROMISE, School of Medicine, University of Palermo, Palermo, Italy.
Cariou B; l'institut du thorax, CHU Nantes, INSERM, CNRS, UNIV Nantes, Nantes, France.
Loy M; Sanofi, Bridgewater, NJ, United States.
Manvelian G; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.
Batsu I; Sanofi, Bridgewater, NJ, United States.
Poulouin Y; IT&M Stats, Paris, France.
Gaudet D; ECOGENE-21 and Clinical Lipidology Unit, Community Gene Medicine Center, Department of Medicine, Université de Montréal, Chicoutimi, QC, Canada.

Arch Med Sci ; 18(2): 285-292, 2022.

Article en En | MEDLINE | ID: mdl-35316922

Palabras clave

PCSK9; cholesterol; low-density lipoprotein; treatment adherence

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arch Med Sci Año: 2022 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google